Schloesser, H. A., Lohneis, A., Garcia-Marquez, M., Thelen, M., Schiller, P., Rosenberger, K., Wennhold, K., Chon, S., Bauer, E., Rudek, L. S., Linde, P., Wirsik, N. M., Fuchs, H. F., Schiffmann, L. M., Buettner, R., Hellmich, M., Bergwelt, M. V., Hillmer, A. M., Bruns, C. J., Zander, T. (2026). Perioperative durvalumab plus neoadjuvant chemoradiotherapy (CROSS) with and without tremelimumab in esophageal adenocarcinoma: The prospective phase II RICE trial (NCT04159974).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4083